← Back to All US Stocks

DH Stock Analysis - Definitive Healthcare Corp. AI Rating

DH Nasdaq Services-Prepackaged Software DE CIK: 0001861795
Recently Updated • Analysis: Mar 23, 2026 • SEC Data: 2025-12-31
SELL
82% Conf
Pending
Analysis scheduled

📊 DH Key Takeaways

Revenue: $241.5M
Net Margin: -57.5%
Free Cash Flow: $37.1M
Current Ratio: 1.64x
Debt/Equity: 0.44x
EPS: $-1.30
AI Rating: SELL with 82% confidence

Investment Thesis

Claude

Despite strong gross margins of 75.9% and positive free cash flow of $37.1M, Definitive Healthcare is unprofitable with significant operating losses (-$224.3M) and negative net income (-$138.9M), indicating operational inefficiency and value destruction. Revenue declined 4.2% YoY while losses persist, suggesting fundamental business model challenges that cash reserves and FCF generation cannot offset.

DH Strengths

Claude
  • + Strong gross margin of 75.9% demonstrates pricing power and customer value in healthcare software
  • + Positive free cash flow of $37.1M with healthy 15.3% FCF margin despite operating losses
  • + Solid balance sheet with $163.6M cash and manageable debt-to-equity ratio of 0.44x provides financial stability

DH Risks

Claude
  • ! Severe operating losses of -$224.3M with -92.9% operating margin indicating fundamental unprofitability despite high gross margins
  • ! Revenue decline of 4.2% YoY combined with deteriorating net losses represents declining business momentum and market traction
  • ! Negative interest coverage of -19.9x cannot sustain debt service long-term; company burning cash operationally despite FCF mask

Key Metrics to Watch

Claude
  • * Revenue growth trajectory and return to positive growth
  • * Operating margin improvement path to profitability
  • * Operating cash flow sustainability as operating losses may eventually reverse FCF generation

DH Financial Metrics

Revenue
$241.5M
Net Income
$-138.9M
EPS (Diluted)
$-1.30
Free Cash Flow
$37.1M
Total Assets
$735.5M
Cash Position
$163.6M

💡 AI Analyst Insight

Definitive Healthcare Corp. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

DH Profitability Ratios

Gross Margin 75.9%
Operating Margin -92.9%
Net Margin -57.5%
ROE -36.7%
ROA -18.9%
FCF Margin 15.3%

DH vs Technology Sector

How Definitive Healthcare Corp. compares to Technology sector averages

Net Margin
DH -57.5%
vs
Sector Avg 18.0%
DH Sector
ROE
DH -36.7%
vs
Sector Avg 22.0%
DH Sector
Current Ratio
DH 1.6x
vs
Sector Avg 2.5x
DH Sector
Debt/Equity
DH 0.4x
vs
Sector Avg 0.5x
DH Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

DH Balance Sheet & Liquidity

Current Ratio
1.64x
Quick Ratio
1.64x
Debt/Equity
0.44x
Debt/Assets
48.5%
Interest Coverage
-19.87x
Long-term Debt
$166.3M

DH 5-Year Financial Trend

DH 5-year financial data: Year 2021: Revenue $166.2M, Net Income $12.9M, EPS N/A. Year 2022: Revenue $222.7M, Net Income $0, EPS $-0.19. Year 2023: Revenue $251.4M, Net Income -$17.8M, EPS $-0.19. Year 2024: Revenue $252.2M, Net Income -$7.2M, EPS $-0.07. Year 2025: Revenue $252.2M, Net Income -$202.4M, EPS $-1.79.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Definitive Healthcare Corp.'s revenue has grown significantly by 52% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.79 indicates the company is currently unprofitable.

DH Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
15.3%
Free cash flow / Revenue

DH Quarterly Performance

Quarterly financial performance data for Definitive Healthcare Corp. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $60.0M -$14.8M $-0.14
Q2 2025 $60.8M -$7.6M $-0.07
Q1 2025 $59.2M -$9.5M $-0.08
Q3 2024 $62.7M -$130.9M $-1.12
Q2 2024 $61.0M -$8.6M $-0.08
Q1 2024 $59.2M -$9.5M $-0.08
Q3 2023 $57.4M -$3.0M $-0.03
Q2 2023 $54.5M -$5.5M $-0.06

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

DH Capital Allocation

Operating Cash Flow
$53.8M
Cash generated from operations
Stock Buybacks
$49.5M
Shares repurchased (TTM)
Capital Expenditures
$16.7M
Investment in assets
Dividends
None
No dividend program

DH SEC Filings

Access official SEC EDGAR filings for Definitive Healthcare Corp. (CIK: 0001861795)

📋 Recent SEC Filings

Date Form Document Action
Mar 3, 2026 4 xslF345X05/ownership.xml View →
Feb 26, 2026 4 xslF345X05/ownership.xml View →
Feb 26, 2026 4 xslF345X05/ownership.xml View →
Feb 26, 2026 4 xslF345X05/ownership.xml View →
Feb 26, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about DH

What is the AI rating for DH?

Definitive Healthcare Corp. (DH) has an AI rating of SELL with 82% confidence, based on fundamental analysis of SEC EDGAR filings.

What are DH's key strengths?

Claude: Strong gross margin of 75.9% demonstrates pricing power and customer value in healthcare software. Positive free cash flow of $37.1M with healthy 15.3% FCF margin despite operating losses.

What are the risks of investing in DH?

Claude: Severe operating losses of -$224.3M with -92.9% operating margin indicating fundamental unprofitability despite high gross margins. Revenue decline of 4.2% YoY combined with deteriorating net losses represents declining business momentum and market traction.

What is DH's revenue and growth?

Definitive Healthcare Corp. reported revenue of $241.5M.

Does DH pay dividends?

Definitive Healthcare Corp. does not currently pay dividends.

Where can I find DH SEC filings?

Official SEC filings for Definitive Healthcare Corp. (CIK: 0001861795) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is DH's EPS?

Definitive Healthcare Corp. has a diluted EPS of $-1.30.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2025-12-31 | Powered by Claude AI